Overview Fundamentals API Earnings EOD API Sample Code Pricing

Landos Biopharma Inc (LABP NASDAQ) stock market data APIs

$ (%) as of June 11, 2024
Price chart is built with Anychart

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc.

Landos Biopharma Inc Financial Data Overview

71 676 K
3 126 K
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'LABP',
Type: 'Common Stock',
Name: 'Landos Biopharma Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00HT2F2R6',
CIK: '1785345',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2021-02-04',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,

Landos Biopharma Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -22 150 000
  • Earnings Per Share -4
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Landos Biopharma Inc Earnings via APIs

  • Latest Release 2024-05-09
  • EPS/Forecast -1

Get Landos Biopharma Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?